ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Other Events
ITEM8.01. OTHER EVENTS.
On February13, 2017, Aldeyra Therapeutics, Inc. issued a press
release announcing that it intended to make a public offering of
its common stock.A copy of the press release is attached hereto
as Exhibit99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
ITEM9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 |
Press Release of Aldeyra Therapeutics, Inc., dated February13, 2017. |
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency. ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Recent Trading Information
ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) closed its last trading session up +0.04 at 4.74 with 77,016 shares trading hands.